The significant quality of life burden associated with symptoms of itching and/or skin pain in patients with atopic dermatitis (AD) may warrant alternate approaches to address unmet needs.
Symptoms of itching and/or skin pain in patients with atopic dermatitis (AD) were associated with significantly worse quality of life (QOL) and more dissatisfaction with condition improvement and treatment, according to study findings from Japan published recently in Current Medical Research and Opinion.
As 2 of the most common and burdensome symptoms associated with AD, itch and skin pain have both been shown in research to have considerable impacts on work productivity and QOL in patients.
Moreover, the presence of comorbidities such as sleep disturbance and mental health disorders, which are more prevalent in those with AD, may further exacerbate risk of adverse health outcomes and lead to higher health care resource utilization.
“It is known that patients with AD in Japan experience a high disease burden due to symptoms affecting sleep, QOL, and work productivity," the authors wrote, in outlining the need for the study. "However, there is limited evidence of the frequency that skin pain is experienced alongside itch and their combined impact on AD patients in Japan."
They conducted an analysis of data derived from the 2020 Adelphi AD Disease Specific Programme (DSP), a point-in-time cross-sectional survey of dermatologists (n = 56) and their patients with a history of moderate to severe AD (N = 265), to assess the incremental dual burden and impact of itch and skin pain on satisfaction, QOL, and work productivity in patients of Japan.
Data were collected between April and September 2019 and stratified by patient characteristics, including having no itch/skin pain (No I/SP, reference group, n = 89), itch/no skin pain (I-only, n = 71), and itch and skin pain (I + SP, n = 26).
QOL was evaluated using the Dermatology Life Quality Index (DLQI; range 0–30); the Patient-Oriented Eczema Measure (POEM) evaluated the presence of AD signs and symptoms in the past week, and their impact on sleep; Work Productivity and Activity Index (WPAI) evaluated AD effects on productivity during the past 7 days (range 0–100). Descriptive analyses were performed alongside a range of regression models, dependent on outcome variables.
Compared with the reference group, patients of the I + SP and I-only groups exhibited significantly worse scores for satisfaction, QOL, and work productivity:
“This dissatisfaction, alongside variations in reported symptomatic burdens, suggests that physicians could consider alternative and/or novel therapeutic approaches for the management of both itch and skin pain,” concluded researchers.
Reference
Torisu-Itakura H, Anderson P, Piercy J, Pike J, Sakamotoa A, Kabashima K. Impact of itch and skin pain on quality of life in adult patients with atopic dermatitis in Japan: results from a real-world, point-in-time, survey of physicians and patients. Curr Med Res Opin. 2022 Jul 5;1-10. doi:10.1080/03007995.2022.2092352
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More